Thomas Drabison
Overview
Explore the profile of Thomas Drabison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
7
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taheri H, Li Y, Huang K, Ahmed E, Jin Y, Drabison T, et al.
Cancer Res Commun
. 2025 Mar;
PMID: 40062557
Aromatase inhibitors (AIs) such as anastrozole, letrozole and exemestane are used as adjuvant treatment for postmenopausal women with hormone receptor-positive breast cancer. The interindividual pharmacokinetic variability seen with AIs is...
2.
Drabison T, Boeckman M, Yang Y, Huang K, de Bruijn P, Nepal M, et al.
Cancer Res Commun
. 2024 Aug;
4(9):2489-2497.
PMID: 39207193
Significance: Despite the established exposure-pharmacodynamic relationships for many TKIs, the mechanisms underlying the agents' unpredictable pharmacokinetic profiles remain poorly understood. We report here that the disposition of many TKIs depends...
3.
Anabtawi N, Drabison T, Jin Y, Eisenmann E, Sparreboom A, Govindarajan R, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2024 Jun;
1242:124209.
PMID: 38905720
Decitabine is a DNA methyltransferase inhibitor used in the treatment of acute myeloid leukemia and myelodysplastic syndrome. The notion that ongoing trials are presently exploring the combined use of decitabine,...
4.
Buck S, Talebi Z, Drabison T, Jin Y, Gibson A, Hu P, et al.
Int J Cancer
. 2024 Mar;
155(2):314-323.
PMID: 38491867
The addition of darolutamide, an androgen receptor signalling inhibitor, to therapy with docetaxel has recently been approved as a strategy to treat metastatic prostate cancer. OATP1B3 is an SLC transporter...
5.
Li Y, Kazuki Y, Drabison T, Kobayashi K, Fujita K, Xu Y, et al.
Drug Metab Dispos
. 2023 Dec;
52(2):80-85.
PMID: 38071551
Previous studies have suggested that the incidence of vincristine-induced peripheral neuropathy (VIPN) is potentially linked with cytochrome P450 (CYP)3A5, a polymorphic enzyme that metabolizes vincristine in vitro, and with concurrent...
6.
Li Y, Drabison T, Nepal M, Ho R, Leblanc A, Gibson A, et al.
JCI Insight
. 2023 Jun;
8(14).
PMID: 37347545
Vincristine is a widely used chemotherapeutic drug for the treatment of multiple malignant diseases that causes a dose-limiting peripheral neurotoxicity. There is no clinically effective preventative treatment for vincristine-induced sensory...
7.
Anabtawi N, Drabison T, Hu S, Sparreboom A, Talebi Z
Expert Opin Drug Metab Toxicol
. 2022 Aug;
18(7-8):459-468.
PMID: 35983889
Introduction: Members of the solute carrier family of organic anion transporting polypeptides are responsible for the cellular uptake of a broad range of endogenous compounds and xenobiotics in multiple tissues....